Wavelength, a subsidiary of SEQENS, is a global API CDMO headquartered in Israel with additional facilities in India and the United States. Founded in 1987, the company provides end-to-end development and manufacturing services for commercial and innovative APIs, HPAPIs, oligonucleotides, steroids, cytotoxics, and advanced intermediates. Wavelength’s capabilities include chemical synthesis, process and analytical development, tech transfer, GMP clinical and commercial manufacturing, spray drying, particle design, enzymatic processes, and scale-up to commercialization.